Loading, Please Wait...
Product and product-related services revenue increased by 119% and 89%, respectively, compared to the three and six-month periods in the prior year
Call scheduled for today, August 6, at 4:30pm ET
TUCSON, Ariz., Aug. 06, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today reported its financial results for the second quarter ended June 30, 2019.
Recent Accomplishments & Highlights:
“We are very pleased to see continued growth in our RUO profiling business coupled with building momentum in our molecular diagnostics business this quarter. We anticipate continued strong performance from both segments throughout the balance of the year as we see positive growth in both our biopharmaceutical customers’ project pipelines and expansion of our relationships with academic medical centers in the United States and in Europe,” said John Lubniewski, President and CEO of HTG. “Collaborative development services revenue declined compared to 2018, as expected this quarter, due to reduced activity in our two active PDP development programs. In the meantime, we continue to actively pursue additional precision diagnostic partnerships with Biopharma partners. As we pass the midpoint of 2019, we remain confident in our ability to continue to execute on our corporate strategy.”
Second Quarter 2019 Financial Results:
Total revenue for the second quarter of 2019 was $5.8 million, an increase of 18% over the same period in the prior year and an 81% increase over the first quarter of 2019. The increase in revenue this quarter was primarily due to the steady growth of the company’s core RUO profiling business.
Product and product-related services revenue for the second quarter of 2019 was $4.4 million, an increase of 119% over the same period in the prior year and a 66% increase over the first quarter of 2019. Collaborative development services revenue for the second quarter of 2019 was $1.4 million compared to $2.9 million in the same period in 2018 and $0.5 million for the first quarter of 2019.
Net loss from operations for the second quarter of 2019 was $4.7 million, compared to $4.1 million for the second quarter of 2018 and $5.3 million for the first quarter of 2019. Net loss per share was $(0.17) for the second quarter of 2019 compared to $(0.14) for the second quarter of 2018 and $(0.19) for the first quarter of 2019.
HTG ended the second quarter with $21.6 million in cash, cash equivalents and short-term available-for-sale securities and current liabilities of approximately $8.0 million plus an additional $15.5 million in non-current liabilities. An additional $3.3 million of restricted cash was held in connection with a convertible note that is included in non-current liabilities as of June 30, 2019.
2019 Revenue Guidance:
The company believes that its total revenue for the full year ending December 31, 2019 will be in the range of $23.0 to $26.0 million.
Conference Call and Webcast:
HTG will host an investment community conference call today beginning at 4:30 p.m. Eastern Time. Conference call and webcast details follow:
|Date:||Tuesday, August 6, 2019|
|Time:||4:30pm Eastern Time|
|Toll Free:||(877) 407-0789|
|HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Its mission is to empower precision medicine.|
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected continued strong performance, growth of various lines of business and our revenue and operational expectations. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that we may not achieve our revenue expectations for 2019; the risk that we may not realize the benefits expected under our collaboration agreements; risks associated with our ability to successfully commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of third party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended June 30, 2019. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
-Financial tables follow-
|HTG Molecular Diagnostics, Inc.|
|Consolidated Statements of Operations|
|Three Months Ended June 30,||Six Months Ended June 30,|
|Product and product-related services||$||4,424,368||$||2,023,312||$||7,086,873||$||3,756,858|
|Collaborative development services||1,371,952||2,887,454||1,912,272||5,312,560|
|Cost of product and product-related services revenue||2,508,371||1,450,682||4,553,898||2,587,745|
|Selling, general and administrative||4,740,710||4,764,751||9,141,576||10,422,583|
|Research and development||3,253,639||2,758,984||5,328,387||5,348,270|
|Total operating expenses||10,502,720||8,974,417||19,023,861||18,358,598|
|Loss on settlement of Growth Term Loan||—||—||—||(105,064||)|
|Interest income (expense), net||(84,022||)||(35,533||)||(136,552||)||(84,887||)|
|Net loss before income taxes||(4,790,422||)||(4,099,184||)||(10,161,268||)||(9,479,131||)|
|Provision for income taxes||6,848||3,545||6,848||3,545|
|Net loss per share, basic and diluted||$||(0.17||)||$||(0.14||)||$||(0.36||)||$||(0.36||)|
|Shares used in computing net loss per share, basic and diluted||28,657,384||28,375,379||28,629,189||26,549,895|
|HTG Molecular Diagnostics, Inc.|
|Consolidated Balance Sheets|
|June 30,||December 31,|
|Cash and cash equivalents||$||11,813,589||$||8,432,600|
|Short-term investments available-for-sale, at fair value||9,753,727||22,681,049|
|Prepaid expenses and other||1,069,180||568,209|
|Total current assets||27,778,281||38,001,145|
|Deferred offering costs||198,088||59,030|
|Deferred MidCap revolving loan costs||59,086||67,068|
|Operating lease right-of-use assets, net||1,394,664||—|
|Property and equipment, net||2,424,625||2,373,790|
|Liabilities and stockholders' equity|
|Contract liabilities - current||486,994||332,711|
|NuvoGen obligation - current||1,286,152||1,290,234|
|MidCap Term Loan payable - current||583,333||—|
|Operating lease liabilities - current||682,863||—|
|Other current liabilities||63,344||186,043|
|Total current liabilities||7,959,539||7,017,374|
|NuvoGen obligation - non-current, net of discount||5,044,263||5,702,519|
|Convertible note, related party - net of debt issuance costs||2,980,940||2,974,213|
|MidCap Term Loan payable - non-current, net of discount and debt issuance costs||6,194,422||6,704,641|
|Operating lease liabilities - non-current||976,786||—|
|Other non-current liabilities||299,049||280,471|
|Commitments and Contingencies|
|Total stockholders’ equity||11,669,992||21,092,062|
|Total liabilities and stockholders' equity||$||35,124,991||$||43,771,280|
LifeSci Advisors, LLC
Phone: (617) 535-7742